Fly News Breaks for January 31, 2020
Jan 31, 2020 | 05:21 EDT
Piper Sandler analyst Edward Tenthoff raised his price target for Vertex Pharmaceuticals (VRTX) to $300 from $284 and reiterates an Overweight rating on the shares following the company's Q4 results. The analyst expects the strong Trikafta launch and drive revenue and earnings upside in 2020. Further, he remains optimistic for a CTX001 update from partner Crispr Therapeutics (CRSP) and other pipeline progress.
News For VRTX;CRSP From the Last 2 Days
There are no results for your query VRTX;CRSP